CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RAMAMURTHY, S.
Right arrow Articles by WINNIE, A. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by RAMAMURTHY, S.
Right arrow Articles by WINNIE, A. P.

Canadian Journal of Anesthesia, Vol 19, 399-411, Copyright © 1972 by Canadian Anesthesiologists' Society

Glycopyrrolate as a Substitute for Atropine in Neostigmine Reversal of Muscle Relaxant Drugs

S. RAMAMURTHY M.D.1, M. H. SHAKER M.D.1, and A. P. WINNIE M.D.1

1 Departments of Anesthesiology, Cook County Hospital and University of Illinois Hospital, Chicago, Illinois

A controlled study was undertaken in man to evaluate glycopyrrolate as a substitute for atropine in anaesthesia by determining the relative ability of the two drugs to protect against the cholinergic challenge provided by neostigmine administered at the conclusion of anaesthesia for reversal of neuromuscular blockade. results indicate that glycopyrrolate offers the same protection against neostigmine-induced bradycardia as atropine with a marked reduction in the magnitude of the initial tachycardia. The dose of glycopyrrolate required to do this is 0.2 mg of neostigmine administered, which is half the dose of atropine required for the same purpose.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1972 by the Canadian Anesthesiologists' Society.